{"id":815318,"date":"2025-02-20T05:51:31","date_gmt":"2025-02-20T10:51:31","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/investors-who-lost-money-on-essa-pharma-inc-epix-should-contact-the-gross-law-firm-about-pending-class-action-epix\/"},"modified":"2025-02-20T05:51:31","modified_gmt":"2025-02-20T10:51:31","slug":"investors-who-lost-money-on-essa-pharma-inc-epix-should-contact-the-gross-law-firm-about-pending-class-action-epix","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/investors-who-lost-money-on-essa-pharma-inc-epix-should-contact-the-gross-law-firm-about-pending-class-action-epix\/","title":{"rendered":"Investors who lost money on ESSA Pharma Inc.(EPIX) should contact The Gross Law Firm about pending Class Action &#8211; EPIX"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>\n        <span class=\"legendSpanClass\"><br \/>\n          <span class=\"xn-location\">NEW YORK<\/span><br \/>\n        <\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">Feb. 20, 2025<\/span><\/span> \/PRNewswire\/ &#8212; The Gross Law Firm issues the following notice to shareholders of\u00a0<b>ESSA Pharma Inc. (NASDAQ: EPIX).<\/b><\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder1\">\n<p>\n          <a href=\"https:\/\/mma.prnewswire.com\/media\/2280333\/The_Gross_Law_Firm_Logo.html\" target=\"_blank\" rel=\"nofollow\"><br \/>\n            <img decoding=\"async\" src=\"https:\/\/mma.prnewswire.com\/media\/2280333\/The_Gross_Law_Firm_Logo.jpg\" title=\"The Gross Law Firm (PRNewsfoto\/The Gross Law Firm)\" alt=\"The Gross Law Firm (PRNewsfoto\/The Gross Law Firm)\" \/><br \/>\n          <\/a>\n        <\/p>\n<\/p><\/div>\n<p>Shareholders who purchased shares of EPIX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.<\/p>\n<p class=\"prntac\">CONTACT US HERE:<\/p>\n<p class=\"prntac\">\n        <a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4366099-16&amp;h=952886028&amp;u=https%3A%2F%2Fsecuritiesclasslaw.com%2Fsecurities%2Fessa-pharma-inc-loss-submission-form%2F%3Fid%3D130529%26from%3D4&amp;a=https%3A%2F%2Fsecuritiesclasslaw.com%2Fsecurities%2Fessa-pharma-inc-loss-submission-form%2F%3Fid%3D130529%26from%3D4\" target=\"_blank\" rel=\"nofollow\">https:\/\/securitiesclasslaw.com\/securities\/essa-pharma-inc-loss-submission-form\/?id=130529&amp;from=4<\/a>\u00a0<\/p>\n<p>\n        <b>CLASS PERIOD: <\/b><br \/>\n        <span class=\"xn-chron\">December 12, 2023<\/span> to <span class=\"xn-chron\">October 31, 2024<\/span><\/p>\n<p>\n        <b>ALLEGATIONS: <\/b>The complaint <span>alleges<\/span> that during the class period, Defendants issued materially false and\/or misleading statements and\/or failed to disclose that: (i) masofaniten in combination with enzalutamide had no clear efficacy benefit over enzalutamide alone; (ii) accordingly, masofaniten in combination with enzalutamide was less effective in treating prostate cancer than defendants had led investors to believe; (iii) the M-E Combination Study, a monotherapy and combination therapy for the treatment of prostate cancer, was unlikely to meet its prespecified Phase 2 primary endpoint; (iv) accordingly, defendants had overstated masofaniten&#8217;s clinical, regulatory, and commercial prospects; and (v) as a result, defendants&#8217; public statements were materially false and misleading at all relevant times.<\/p>\n<p>\n        <b>DEADLINE: <span class=\"xn-chron\">March 25, 2025<\/span><\/b> Shareholders should not delay in registering for this class action. Register your information here: <a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4366099-16&amp;h=952886028&amp;u=https%3A%2F%2Fsecuritiesclasslaw.com%2Fsecurities%2Fessa-pharma-inc-loss-submission-form%2F%3Fid%3D130529%26from%3D4&amp;a=https%3A%2F%2Fsecuritiesclasslaw.com%2Fsecurities%2Fessa-pharma-inc-loss-submission-form%2F%3Fid%3D130529%26from%3D4\" target=\"_blank\" rel=\"nofollow\">https:\/\/securitiesclasslaw.com\/securities\/essa-pharma-inc-loss-submission-form\/?id=130529&amp;from=4<\/a>\u00a0<\/p>\n<p>\n        <b>NEXT STEPS FOR SHAREHOLDERS: <\/b>Once you register as a shareholder who purchased shares of EPIX during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is <span class=\"xn-chron\">March 25, 2025<\/span>. There is no cost or obligation to you to participate in this case.<\/p>\n<p>\n        <b>WHY GROSS LAW FIRM? <\/b>The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, <span>fraud<\/span>, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and\/or misleading statements or the omission of material information by a company lead to artificial inflation of the company&#8217;s stock. Attorney advertising. Prior results do not guarantee similar outcomes.<\/p>\n<p>\n        <b>CONTACT:<\/b><br \/>\n        <br \/>The Gross Law Firm<br \/>15 West 38th Street, 12th floor<br \/><span class=\"xn-location\">New York, NY<\/span>, 10018<br \/>Email: <a href=\"mailto:dg@securitiesclasslaw.com\" target=\"_blank\" rel=\"nofollow\">dg@securitiesclasslaw.com<\/a>\u00a0<br \/>Phone: (646) 453-8903<\/p>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=NY22965&amp;sd=2025-02-20\" \/> View original content to download multimedia:<a id=\"PRNURL\" rel=\"nofollow\" href=\"https:\/\/www.prnewswire.com\/news-releases\/investors-who-lost-money-on-essa-pharma-incepix-should-contact-the-gross-law-firm-about-pending-class-action---epix-302380661.html\" target=\"_blank\">https:\/\/www.prnewswire.com\/news-releases\/investors-who-lost-money-on-essa-pharma-incepix-should-contact-the-gross-law-firm-about-pending-class-action&#8212;epix-302380661.html<\/a><\/p>\n<p>SOURCE  The Gross Law Firm<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=NY22965&amp;Transmission_Id=202502200545PR_NEWS_USPR_____NY22965&amp;DateId=20250220\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire NEW YORK , Feb. 20, 2025 \/PRNewswire\/ &#8212; The Gross Law Firm issues the following notice to shareholders of\u00a0ESSA Pharma Inc. (NASDAQ: EPIX). Shareholders who purchased shares of EPIX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https:\/\/securitiesclasslaw.com\/securities\/essa-pharma-inc-loss-submission-form\/?id=130529&amp;from=4\u00a0 CLASS PERIOD: December 12, 2023 to October 31, 2024 ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and\/or misleading statements and\/or failed to disclose that: (i) masofaniten in combination with enzalutamide had no clear efficacy benefit over enzalutamide alone; (ii) accordingly, masofaniten in combination with enzalutamide was less effective in treating prostate &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/investors-who-lost-money-on-essa-pharma-inc-epix-should-contact-the-gross-law-firm-about-pending-class-action-epix\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Investors who lost money on ESSA Pharma Inc.(EPIX) should contact The Gross Law Firm about pending Class Action &#8211; EPIX&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-815318","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Investors who lost money on ESSA Pharma Inc.(EPIX) should contact The Gross Law Firm about pending Class Action - EPIX - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/investors-who-lost-money-on-essa-pharma-inc-epix-should-contact-the-gross-law-firm-about-pending-class-action-epix\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Investors who lost money on ESSA Pharma Inc.(EPIX) should contact The Gross Law Firm about pending Class Action - EPIX - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire NEW YORK , Feb. 20, 2025 \/PRNewswire\/ &#8212; The Gross Law Firm issues the following notice to shareholders of\u00a0ESSA Pharma Inc. (NASDAQ: EPIX). Shareholders who purchased shares of EPIX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https:\/\/securitiesclasslaw.com\/securities\/essa-pharma-inc-loss-submission-form\/?id=130529&amp;from=4\u00a0 CLASS PERIOD: December 12, 2023 to October 31, 2024 ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and\/or misleading statements and\/or failed to disclose that: (i) masofaniten in combination with enzalutamide had no clear efficacy benefit over enzalutamide alone; (ii) accordingly, masofaniten in combination with enzalutamide was less effective in treating prostate &hellip; Continue reading &quot;Investors who lost money on ESSA Pharma Inc.(EPIX) should contact The Gross Law Firm about pending Class Action &#8211; EPIX&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/investors-who-lost-money-on-essa-pharma-inc-epix-should-contact-the-gross-law-firm-about-pending-class-action-epix\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-02-20T10:51:31+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/2280333\/The_Gross_Law_Firm_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investors-who-lost-money-on-essa-pharma-inc-epix-should-contact-the-gross-law-firm-about-pending-class-action-epix\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investors-who-lost-money-on-essa-pharma-inc-epix-should-contact-the-gross-law-firm-about-pending-class-action-epix\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Investors who lost money on ESSA Pharma Inc.(EPIX) should contact The Gross Law Firm about pending Class Action &#8211; EPIX\",\"datePublished\":\"2025-02-20T10:51:31+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investors-who-lost-money-on-essa-pharma-inc-epix-should-contact-the-gross-law-firm-about-pending-class-action-epix\\\/\"},\"wordCount\":435,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investors-who-lost-money-on-essa-pharma-inc-epix-should-contact-the-gross-law-firm-about-pending-class-action-epix\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2280333\\\/The_Gross_Law_Firm_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investors-who-lost-money-on-essa-pharma-inc-epix-should-contact-the-gross-law-firm-about-pending-class-action-epix\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investors-who-lost-money-on-essa-pharma-inc-epix-should-contact-the-gross-law-firm-about-pending-class-action-epix\\\/\",\"name\":\"Investors who lost money on ESSA Pharma Inc.(EPIX) should contact The Gross Law Firm about pending Class Action - EPIX - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investors-who-lost-money-on-essa-pharma-inc-epix-should-contact-the-gross-law-firm-about-pending-class-action-epix\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investors-who-lost-money-on-essa-pharma-inc-epix-should-contact-the-gross-law-firm-about-pending-class-action-epix\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2280333\\\/The_Gross_Law_Firm_Logo.jpg\",\"datePublished\":\"2025-02-20T10:51:31+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investors-who-lost-money-on-essa-pharma-inc-epix-should-contact-the-gross-law-firm-about-pending-class-action-epix\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investors-who-lost-money-on-essa-pharma-inc-epix-should-contact-the-gross-law-firm-about-pending-class-action-epix\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investors-who-lost-money-on-essa-pharma-inc-epix-should-contact-the-gross-law-firm-about-pending-class-action-epix\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2280333\\\/The_Gross_Law_Firm_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2280333\\\/The_Gross_Law_Firm_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investors-who-lost-money-on-essa-pharma-inc-epix-should-contact-the-gross-law-firm-about-pending-class-action-epix\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Investors who lost money on ESSA Pharma Inc.(EPIX) should contact The Gross Law Firm about pending Class Action &#8211; EPIX\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Investors who lost money on ESSA Pharma Inc.(EPIX) should contact The Gross Law Firm about pending Class Action - EPIX - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/investors-who-lost-money-on-essa-pharma-inc-epix-should-contact-the-gross-law-firm-about-pending-class-action-epix\/","og_locale":"en_US","og_type":"article","og_title":"Investors who lost money on ESSA Pharma Inc.(EPIX) should contact The Gross Law Firm about pending Class Action - EPIX - Market Newsdesk","og_description":"PR Newswire NEW YORK , Feb. 20, 2025 \/PRNewswire\/ &#8212; The Gross Law Firm issues the following notice to shareholders of\u00a0ESSA Pharma Inc. (NASDAQ: EPIX). Shareholders who purchased shares of EPIX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https:\/\/securitiesclasslaw.com\/securities\/essa-pharma-inc-loss-submission-form\/?id=130529&amp;from=4\u00a0 CLASS PERIOD: December 12, 2023 to October 31, 2024 ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and\/or misleading statements and\/or failed to disclose that: (i) masofaniten in combination with enzalutamide had no clear efficacy benefit over enzalutamide alone; (ii) accordingly, masofaniten in combination with enzalutamide was less effective in treating prostate &hellip; Continue reading \"Investors who lost money on ESSA Pharma Inc.(EPIX) should contact The Gross Law Firm about pending Class Action &#8211; EPIX\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/investors-who-lost-money-on-essa-pharma-inc-epix-should-contact-the-gross-law-firm-about-pending-class-action-epix\/","og_site_name":"Market Newsdesk","article_published_time":"2025-02-20T10:51:31+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/2280333\/The_Gross_Law_Firm_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investors-who-lost-money-on-essa-pharma-inc-epix-should-contact-the-gross-law-firm-about-pending-class-action-epix\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investors-who-lost-money-on-essa-pharma-inc-epix-should-contact-the-gross-law-firm-about-pending-class-action-epix\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Investors who lost money on ESSA Pharma Inc.(EPIX) should contact The Gross Law Firm about pending Class Action &#8211; EPIX","datePublished":"2025-02-20T10:51:31+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investors-who-lost-money-on-essa-pharma-inc-epix-should-contact-the-gross-law-firm-about-pending-class-action-epix\/"},"wordCount":435,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investors-who-lost-money-on-essa-pharma-inc-epix-should-contact-the-gross-law-firm-about-pending-class-action-epix\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/2280333\/The_Gross_Law_Firm_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investors-who-lost-money-on-essa-pharma-inc-epix-should-contact-the-gross-law-firm-about-pending-class-action-epix\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/investors-who-lost-money-on-essa-pharma-inc-epix-should-contact-the-gross-law-firm-about-pending-class-action-epix\/","name":"Investors who lost money on ESSA Pharma Inc.(EPIX) should contact The Gross Law Firm about pending Class Action - EPIX - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investors-who-lost-money-on-essa-pharma-inc-epix-should-contact-the-gross-law-firm-about-pending-class-action-epix\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investors-who-lost-money-on-essa-pharma-inc-epix-should-contact-the-gross-law-firm-about-pending-class-action-epix\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/2280333\/The_Gross_Law_Firm_Logo.jpg","datePublished":"2025-02-20T10:51:31+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investors-who-lost-money-on-essa-pharma-inc-epix-should-contact-the-gross-law-firm-about-pending-class-action-epix\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/investors-who-lost-money-on-essa-pharma-inc-epix-should-contact-the-gross-law-firm-about-pending-class-action-epix\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investors-who-lost-money-on-essa-pharma-inc-epix-should-contact-the-gross-law-firm-about-pending-class-action-epix\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/2280333\/The_Gross_Law_Firm_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/2280333\/The_Gross_Law_Firm_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investors-who-lost-money-on-essa-pharma-inc-epix-should-contact-the-gross-law-firm-about-pending-class-action-epix\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Investors who lost money on ESSA Pharma Inc.(EPIX) should contact The Gross Law Firm about pending Class Action &#8211; EPIX"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/815318","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=815318"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/815318\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=815318"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=815318"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=815318"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}